Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers

Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers

BackgroundImmune checkpoint inhibitor (ICI) therapy has been described to markedly improve patient survival. However, reports describing the antitumor therapeutic efficacy and safety of ICIs in patients with autoantibodies are scarce.MethodsThis study examined the efficacy and feasibility of ICIs in...

Full description

Bibliographic Details
Main Authors: Atsuto Mouri, Kyoichi Kaira, Ou Yamaguchi, Kosuke Hashimoto, Yu Miura, Ayako Shiono, Shun Shinomiya, Tomoe Akagami, Hisao Imai, Kunihiko Kobayashi, Hiroshi Kagamu
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Oncology
Subjects:
antinuclear antibodies
immune-check point inhibitor
non-small cell lung cancer
immune-related adverse events
feasibility
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.610952/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.610952/full

Similar Items